Researchers at the Icahn School of Medicine at Mount Sinai have developed an advanced artificial intelligence (AI)-driven tool to improve the management and prognosis of prostate cancer.
Details on the findings were reported in the September 20 online issue of European Urology [https://doi.org/10.1016/j.eururo.2024.07.013].
The tool, PATHOMIQ_PRAD, designed for patients with intermediate-risk prostate cancer, uses deep learning to extract morphological features from datasets derived from biopsy or surgical hematoxylin- and eosin-stained whole-slide images. It aims to identify those at higher risk of rapid disease progression and provide more timely, accurate predictions for earlier interventions and more targeted, personalized, treatment plans.
PATHOMIQ_PRAD scores range from 0 to 1, with higher scores indicating high-risk features. The study analyzed large datasets to classify patients into high- and low-risk groups using pre-determined PATHOMIQ_PRAD clinical cut offs of 0.45 for BCR and 0.55 for metastasis. These limits were based on things like the chances of cancer returning or spreading. The study found that the tool outperformed existing benchmark cancer outcomes over the next five years compared to other current tools.
The paper is titled “A Novel Artificial Intelligence–powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk.”
